ClinicalTrials.gg
CompletedNCT05411588Updated Nov 17, 2026

A Study to Learn How the Study Medicine Called PF-07275315 Works in Healthy People

A Phase 1 interventional study of PF-07275315 and Placebo in Healthy Volunteers, sponsored by Pfizer. Completed at 5 sites in 2 countries. Open to participants aged 18 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-11-17.

Sponsored by Pfizer · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Primary completion was May 2024, 2 years 6 months ago, and no results have been posted to the registry.
Updated Nov 17, 20261 site added1 site removedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
65
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Study summary

The purpose of this clinical trial is to learn about the safety and effects of the study medicine (called PF-07275315) in healthy participants.

This study is seeking participants who:

  • Are healthy as determined by medical evaluation.
  • Are willing and able to comply with all scheduled visits, treatment plan, laboratory tests, lifestyle considerations, and other study procedures.
  • Have a body mass index (BMI) of 17.5 to 32 kilogram per meter square - a total body weight of more than 50 kilograms (110 pounds)

Participants will be divided randomly into 8 different groups. All participants will receive either one PF-07275315 or a harmless treatment that has no medical effect (placebo) intravenous (IV) infusion (given directly into a vein). Participants will take part in this study for up to 541 days. During this time, eligible participants will receive single increasing amounts of PF-07275315 or placebo. Increase will only occur if the sponsor agrees that the next dose is likely to have acceptable safety and tolerability. The follow-up visit will take place 271 days after first treatment.

Read the detailed description

This is an first-in-human within-cohort randomized, participant- and investigator-blind, sponsor-open, placebo-controlled study of the safety, tolerability, PK, and PD following single and multiple escalating doses of PF-07275315 that will be conducted in healthy adults.

02

Conditions studied

  • Healthy Volunteers

Keywords

  • PF-07275315
03

In context

Lead sponsor

Pfizer is the lead sponsor of 3,337 studies on the registry; 148 are open to participants now.

Of its 601 completed or terminated interventional studies of FDA-regulated products, 392 (65%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Eligibility criteria

This study is seeking participants who:

  • Are overtly healthy as determined by medical evaluation.
  • Are willing and able to comply with all scheduled visits, treatment plan, laboratory tests, lifestyle considerations, and other study procedures.
  • Have a (BMI) of 17.5 to 32 kg/m2; and a total body weight >50 kg (110 lb).

This study is not seeking participants who have:

  • Evidence of active, latent, or inadequately treated infection with Mycobacterium tuberculosis (TB) as defined by both of the following
  • History of (HIV) infection, , or ;
  • Any of the following acute or chronic infections or infection history
  • Any or have a history of malignancies with the exception of adequately treated or excised non- basal cell or squamous cell cancer of the skin, or cervical carcinoma in situ.
  • Have undergone significant trauma or major surgery within 1 month of the first dose of study drug.
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Sequential assignment
Masking
Double (Participant, Investigator)
Enrollment
65 participants (actual)

Study arms

  • Experimental
    Active

    PF-07275315

    Drug: PF-07275315

  • Placebo comparator
    Placebo

    Placebo

    Drug: Placebo

Interventions

  • Active drug

    Also known as: No other name

  • DrugPlacebo

    Placebo

    Also known as: No other name

06

What researchers measure

Primary outcomes

  1. Number of participants with Adverse Events (AEs)

    Incidence and severity of AEs

    Time frame: Baseline through study completion, approximately 561 days

  2. Number of participants with clinically meaningful change from baseline in laboratory Tests Results

    Number of Participants With Change From Baseline in Laboratory Tests Results

    Time frame: Baseline through study completion, approximately 561 days

  3. Number of participants with clinically meaningful change from baseline in vital signs

    Number of participants with change from baseline in vital signs

    Time frame: Baseline through study completion, approximately 561 days

  4. Number of participants with Serious AEs (SAEs)

    Incidence and severity of SAEs

    Time frame: Baseline through study completion, approximately 561 days

  5. Number of participants with clinically meaningful change from baseline in ECG parameters

    number of participants with change from baseline in ECG parameters

    Time frame: Baseline through study completion, approximately 561 days

Secondary outcomes

  1. Maximum Plasma Concentration (Cmax)

    Cmax will be observed directly from data.

    Time frame: 1- 561 Days

  2. Time to Maximum Plasma Concentration (Tmax) of PF-07275315

    Tmax will be observed directly from data.

    Time frame: 1 - 561 Days

  3. Area under the plasma concentration-time curve from time 0 to the time of the last quantifiable concentration (AUClast) of PF-07275315

    Area under the plasma concentration-time curve from time 0 to the time of the last quantifiable concentration (AUClast)

    Time frame: 1 - 561 Days

  4. Incidence of the development of Antidrug antibodies (ADA) against PF-07275315

    To evaluate the immunogenicity profile of PF-07275315 in healthy adults.

    Time frame: 1 - 561 Days

  5. Half-life of PF-07275315

    terminal elimination half-life will be measured

    Time frame: 1-561 days

  6. Area under the curve (AUC) of PF-07275315 serum concentration time-profile from time zero extrapolated to infinite time

    AUCinf

    Time frame: 1-561 days

  7. AUC of PF-07275315 serum concentration time-profile over the dosing interval of 2 weeks or 336 hours

    AUC336

    Time frame: 1-561 days

  8. Incidence of the development of neutralizing antibodies (NAb) against PF-07275315

    To evaluate the immunogenicity profile of PF-07275315 in healthy adults.

    Time frame: 1-561 days

07

Study locations

5 sites
  • Orange County Research Center
    Lake Forest, California 92630, United States
  • Orange County Research Center
    Tustin, California 92780, United States
  • New Haven Clinical Research Unit
    New Haven, Connecticut 06511, United States
  • Qps-Mra, Llc
    South Miami, Florida 33143, United States
  • Pfizer Clinical Research Unit - Brussels
    Brussels, Bruxelles-capitale, Région de B-1070, Belgium
08

References and documents

Individual participant data

Plan to share: No — Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jun 2022 to primary completion in May 2024, 23 months.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 6, 2022
First posted
Jun 9, 2022
StartActual
Jun 9, 2022
Primary completionActual
May 13, 2024
CompletionActual
May 13, 2024
Last update
Nov 17, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
1 site added, 1 site removed
Show site
  • Pfizer Clinical Research Unit - Brussels · Brussels, Belgium
Show 1 removed
  • Pfizer Clinical Research Unit - Brussels · Brussels, Belgium
Nov 17, 2026
Show all 1 update
  1. Nov 17, 2026
    1 site added, 1 site removed
    Show site
    • Pfizer Clinical Research Unit - Brussels · Brussels, Belgium
    Show 1 removed
    • Pfizer Clinical Research Unit - Brussels · Brussels, Belgium
    + 3 other changes: verification date, references and data sharing statement

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT05411588
Lead sponsor
Pfizer
Responsible party
Sponsor
First posted
Jun 9, 2022
Start date
Jun 9, 2022
Primary completion
May 13, 2024
Completion
May 13, 2024
Last update
Nov 17, 2026

Study contacts

Pfizer CT.gov Call Center
study director · Pfizer

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Tilrekimig

Start the discussion